Evolus, Inc. (EOLS)
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Last price
- $7.51
- As of
Kresmion compiles this page from EOLS's SEC filings, its 13F institutional holders and the market events Kresmion detects, each linked to its source.
Evolus, Inc. (EOLS): 5 institutional managers tracked by Kresmion reported non-option positions in their 2026Q2 Form 13F filings, and the most recent SEC filing on record for the company is a Form 8-K filed 2026-08-05.
See the full EOLS dossier
Price with insider and filing markers, who is positioning, fundamentals and peers for EOLS on one page. Preview it with sample data, then open it live with a free account.
Preview the EOLS dossierActive signals for EOLS
- lowEARNINGS_BEAT
Q2-2026: EPS $0.02 vs $-0.0352 estimate, +0.06 on a near-zero consensus
- highINSTITUTIONAL_SURGE
CITADEL ADVISORS LLC added +3856% to EOLS (2026Q2)
- mediumNEW_POSITION
Point72 Asset Management, L.P. new position in EOLS
- highINSTITUTIONAL_EXIT
RENAISSANCE TECHNOLOGIES LLC cut 58% of EOLS (2026Q1)
- highINSTITUTIONAL_EXIT
D. E. Shaw & Co., Inc. cut 64% of EOLS (2026Q1)
FREE, NO ACCOUNT
Every signal on EOLS, as it fires
You are seeing 5 of 9 signals recorded on EOLS since 2026-05-29.
The five above landed across 3 days. The other 4 were recorded on 2 other days.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
Largest reported share positions in EOLS (2026Q2)
| Manager / security | Market value | % portfolio | QoQ |
|---|---|---|---|
| MILLENNIUM MANAGEMENT LLCCUSIP 30052C107 · 2026Q2 | $12.4M | 0.00% | , |
| Point72 Asset Management, L.P.CUSIP 30052C107 · 2026Q2 | $10.5M | 0.01% | , |
| CITADEL ADVISORS LLCCUSIP 30052C107 · 2026Q2 | $3.5M | 0.00% | , |
| D. E. Shaw & Co., Inc.CUSIP 30052C107 · 2026Q2 | $2.3M | 0.00% | , |
| RENAISSANCE TECHNOLOGIES LLCCUSIP 30052C107 · 2026Q2 | $2.1M | 0.00% | , |
Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.
Recent SEC filings, EOLS
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-KSEC EDGAR ↗
EOLS against its peers
EOLS's operating margin of -11.0% ranks in the 42nd percentile of 17 Drug Manufacturers - Specialty & Generic sub-industry peers, fiscal periods ending between 2025-12-31 and 2026-05-31.
| Metric | EOLS | Peer median | Percentile | n |
|---|---|---|---|---|
| Revenue FY | 297M USD | 208M USD | 74 | 16 |
| Gross margin | 66.3% | 48.9% | 89 | 13 |
| Operating margin | -11.0% | -4.3% | 42 | 17 |
| Net margin | -17.4% | -18.7% | 53 | 17 |
| Return on equity | n/a | -19.9% | n/a | 16 |
| 1 year | 25.2% | -30.4% | 79 | 16 |
Peers (19): TLRY, VREOF, KMDA, NIKA, AQST, TKNO, VRNO, CGC, ELTP, CRLBF, HROW, ADCT, CRON, AKBA, GTBIF, ETON, TSNDF, DERM, CRDL. Left out: EVO (period gap), BORAY (no annual filing), LFCR (no annual filing), PHBI (period gap), ASRT (no annual filing), OGI (period gap). Fiscal periods ending between 2025-12-31 and 2026-05-31. Every figure is one full fiscal year read from one annual filing (EOLS: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.
Related tickers
Follow EOLS on a live board
Kresmion is a cross-asset market-intelligence terminal. Open a board scoped to EOLS for its filings, 13F changes, insider trades, options positioning, and confluence read in one view, each with its source.